Premium
Evaluation of the incidence and risk of hypoglycemic coma associated with selection of basal insulin in the treatment of diabetes: a Finnish register linkage study
Author(s) -
Haukka Jari,
Hoti Fabian,
Erästö Panu,
Saukkonen Tero,
Mäkimattila Sari,
Korhonen Pasi
Publication year - 2013
Publication title -
pharmacoepidemiology and drug safety
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.023
H-Index - 96
eISSN - 1099-1557
pISSN - 1053-8569
DOI - 10.1002/pds.3534
Subject(s) - medicine , insulin glargine , insulin detemir , insulin , nph insulin , hypoglycemia , hazard ratio , diabetes mellitus , type 2 diabetes , endocrinology , glycemic , confidence interval
Objective Long‐acting basal insulin analogs have demonstrated positive effects on the balance between effective glycemic control and risk of hypoglycemia versus neutral protamine Hagedorn (NPH) insulin in randomized controlled trials. Evidence of severe hypoglycemic risk with insulin detemir, insulin glargine, or NPH insulin is presented from a nationwide retrospective database study. Research design and methods Data from hospital and secondary healthcare visits due to hypoglycemic coma from 75 682 insulin‐naïve type 1 or 2 diabetes patients initiating therapy with NPH insulin, insulin glargine, or insulin detemir in Finland between 2000 and 2009 were analyzed. Incidence rates with 95% confidence intervals (CIs) were calculated using Poisson regression. Hazard ratios were estimated using Cox's regression with adjustments for relevant background variables. Results The adjusted risk of hospital/secondary healthcare visits due to the first severe hypoglycemic event was 21.7% (95% CI 9.6–32.1%, p < 0.001) lower for insulin detemir and 9.9% (95% CI 1.5–17.6%, p = 0.022) lower for insulin glargine versus NPH insulin. Risk of hypoglycemic coma recurrence was 36.3% (95% CI 8.9–55.5%, p = 0.014) lower for detemir and 9.5% but not significantly (95% CI −10.2 to 25.7%, p = 0.318) lower for glargine versus NPH insulin. Risk of all hypoglycemic coma events was 30.8% (95% CI 16.2–42.8%, p ‐value <0.001) lower for detemir and 15.6% (95% CI 5.1–25.0%, p ‐value 0.005) lower for glargine versus NPH. Insulin detemir had a significantly lower risk for first (13.1% lower [ p = 0.034]), recurrent (29.6% lower [ p = 0.021]), and all (17.9% lower [ p = 0.016]) severe hypoglycemic events than insulin glargine. Conclusions There were considerable differences in risk of hospitalization or secondary healthcare visits due to hypoglycemic coma between basal insulin treatments in real‐life clinical practice. © 2013 The Authors. Pharmacoepidemiology and Drug Safety published by John Wiley & Sons, Ltd.